The absence of any institutional selling and the doubling of stakes by two mega-passive firms signals strong conviction in ACRS at current levels. Traders should monitor for follow-on retail or active manager interest, especially if this coincides with upcoming clinical or regulatory catalysts.
Executive Summary
Three major institutional investors — Morgan Stanley, UBS, and Schwab — significantly increased their positions in Aclaris Therapeutics (ACRS) during Q4 2024, collectively adding $2.3M in new holdings with no institutional selling detected. This coordinated accumulation by large passive managers suggests growing institutional interest despite the company's small market cap of $311M.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.3M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +122.9% | $2.7M | $2.1M |
| UBS | DOUBLED | +118.1% | $172.0K | $136.0K |
| Schwab | NEW | +0% | $82.0K | $82.0K |
Key Facts
- Morgan Stanley doubled its stake, increasing value by $2.1M (from $553K to $2.7M)
- UBS doubled its position, adding $136K in value (from $37K to $172K)
- Schwab initiated a new position worth $82K
- No institutional selling occurred in this quarter
- Total net buying: $2.3M across three mega-passive institutions
Financial Impact
3 institutions accumulated $2.3M in net new positions, increasing total institutional holding value by $2.3M to $2.9M
Risk Factors
- All buyers are passive managers, suggesting index-driven or rebalancing activity rather than active conviction
- Small absolute dollar size of moves ($2.9M total holdings) limits immediate price impact
- Low market cap stock remains vulnerable to volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ACRS-2024-Q4 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | — |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | — |
Apr 28, 2026 25w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | — |
Apr 28, 2026 25w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | — |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | — |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | — |
Mar 20, 2026 31w ago | Press Release | $3.69 $3.52 | ▼ −4.61% | ▼ −2.46% | — |
Mar 18, 2026 31w ago | Press Release | $3.66 $3.59 | ▼ −1.91% | ▼ −1.20% | — |
Mar 11, 2026 32w ago | 8-K | $3.51 $3.74 | ▲ +6.55% | ▲ +7.53% | — |
Feb 28, 2026 34w ago | Institutional Cluster | $3.05 $3.39 | ▲ +11.15% | ▲ +12.36% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers